Throw back Thursday: Stefan Müller-Hülsbeck et al. report the 3-year results of the MAJESTIC first-in-human study of the Eluvia Drug-Eluting Vascular Stent System for treating femoropopliteal artery lesions: https://t.co/wSaCoXbSpg @Herzzentrum @ZOLziekenh
RT @CVIR_Journal: Miltos K's article tip: 83.5% primary patency on 24-month Duplex & 85.3% freedom from TLR on 36-month clinical follow-up…
RT @CVIR_Journal: Miltos K's article tip: 83.5% primary patency on 24-month Duplex & 85.3% freedom from TLR on 36-month clinical follow-up…
RT @CVIR_Journal: Miltos K's article tip: 83.5% primary patency on 24-month Duplex & 85.3% freedom from TLR on 36-month clinical follow-up…
RT @CVIR_Journal: Miltos K's article tip: 83.5% primary patency on 24-month Duplex & 85.3% freedom from TLR on 36-month clinical follow-up…
RT @CVIR_Journal: Miltos K's article tip: 83.5% primary patency on 24-month Duplex & 85.3% freedom from TLR on 36-month clinical follow-up…
RT @CVIR_Journal: Miltos K's article tip: 83.5% primary patency on 24-month Duplex & 85.3% freedom from TLR on 36-month clinical follow-up…
Miltos K's article tip: 83.5% primary patency on 24-month Duplex & 85.3% freedom from TLR on 36-month clinical follow-up from the multicenter MAJESTIC trial for 57 patients with SFA lesions #IRad #MIIP https://t.co/fVIivenChx @bostonsci @ZOLziekenhuis
The 3-year results of the MAJESTIC Trial: 85.3% freedom from TLR, 0 stent fracture #IRad @Herzzentrum @ZOLziekenhuis https://t.co/OOfk0JBftS https://t.co/rtVhv9adrp